Shares of Harrow Health (NASDAQ:HROW) saw unusually-high trading volume on Friday . Approximately 1,078,420 shares changed hands during mid-day trading, an increase of 333% from the previous session’s volume of 249,061 shares.The stock last traded at $6.11 and had previously closed at $5.86.
HROW has been the subject of a number of research reports. Zacks Investment Research downgraded Harrow Health from a “hold” rating to a “sell” rating in a research report on Wednesday, March 13th. TheStreet upgraded Harrow Health from a “d-” rating to a “c” rating in a research report on Wednesday, May 1st. Finally, ValuEngine downgraded Harrow Health from a “hold” rating to a “sell” rating in a research report on Wednesday, March 27th.
The company has a quick ratio of 3.22, a current ratio of 3.43 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $144.74 million, a P/E ratio of 10.08 and a beta of -0.02.
Harrow Health (NASDAQ:HROW) last announced its quarterly earnings data on Tuesday, March 12th. The company reported $0.77 EPS for the quarter, missing the Zacks’ consensus estimate of $0.84 by ($0.07). Harrow Health had a return on equity of 100.84% and a net margin of 65.84%. The firm had revenue of $11.38 million during the quarter, compared to the consensus estimate of $10.92 million. On average, equities analysts expect that Harrow Health will post -0.1 earnings per share for the current year.
In related news, Director Robert J. Kammer sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $6.91, for a total transaction of $69,100.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 30,000 shares of company stock valued at $162,500 in the last 90 days. 12.43% of the stock is owned by corporate insiders.
Several institutional investors have recently bought and sold shares of HROW. Birchview Capital LP bought a new position in shares of Harrow Health during the 1st quarter worth approximately $896,000. JPMorgan Chase & Co. bought a new position in shares of Harrow Health during the 1st quarter worth approximately $168,000. FineMark National Bank & Trust bought a new position in shares of Harrow Health during the 1st quarter worth approximately $113,000. Acadian Asset Management LLC bought a new position in shares of Harrow Health during the 1st quarter worth approximately $1,983,000. Finally, Alambic Investment Management L.P. bought a new position in shares of Harrow Health during the 1st quarter worth approximately $252,000. Institutional investors and hedge funds own 24.18% of the company’s stock.
About Harrow Health (NASDAQ:HROW)
Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.
Featured Article: Recession
Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.